Implications of the U.S. Food and Drug Administration warning against the use of sildenafil for the treatment of pediatric pulmonary hypertension.
about
Insight into Pulmonary Arterial Hypertension Associated with Congenital Heart Disease (PAH-CHD): Classification and Pharmacological Management from a Pediatric Cardiological Point of ViewDrug treatment of pulmonary hypertension in childrenOxidative Stress and Therapeutic Development in Lung DiseasesPediatric pulmonary arterial hypertension.Update in pulmonary vascular diseases 2013.Addressing the challenges of phenotyping pediatric pulmonary vascular diseaseAcute onset of bilateral visual loss during sildenafil therapy in a young infant with congenital heart diseaseCharacteristics of pediatric pulmonary hypertension trials registered on ClinicalTrials.gov.Progress in the diagnosis and management of pulmonary hypertension in children.The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseasesPulmonary hypertension in bronchopulmonary dysplasiaPharmacologic strategies in neonatal pulmonary hypertension other than nitric oxide.Pediatric Cardiac Intensive Care Society 2014 Consensus Statement: Pharmacotherapies in Cardiac Critical Care Pulmonary Hypertension.Sildenafil in pediatric pulmonary arterial hypertension.Sildenafil exposure and hemodynamic effect after Fontan surgeryDisrupted pulmonary artery cyclic guanosine monophosphate signaling in mice with hyperoxia-induced pulmonary hypertension.Pediatric Exercise Testing: Value and Implications of Peak Oxygen UptakeCongenital Diaphragmatic hernia - a review.Update in pulmonary vascular diseases 2012.Nitric oxide deficiency and endothelial dysfunction in pulmonary arterial hypertension.Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment.Update in pediatric lung disease 2013.Current and advancing treatments for pulmonary arterial hypertension in childhood.Sildenafil for the treatment of pulmonary hypertension in children.Treatment of pulmonary arterial hypertension in children.Risk-benefit considerations when prescribing phosphodiesterase-5 inhibitors in children.Current Concepts in Management of Pulmonary Hypertension: Fighting the Old Demon with Modern Weapons.Pulmonary Hypertension and Vascular Abnormalities in Bronchopulmonary Dysplasia.Pulmonary hypertension in the premature infant: a challenging comorbidity in a vulnerable population.New guidelines for managing pulmonary hypertension: what the pediatrician needs to know.Drug utilisation profile in the neonatal unit of a university hospital: a prospective observational study in Brazil.Iloprost drug delivery during infant conventional and high-frequency oscillatory ventilation.Looking beyond PPHN: the unmet challenge of chronic progressive pulmonary hypertension in the newbornSubstantially increased sildenafil bioavailability after sublingual administration in children with congenital heart disease: two case reports.Executive Summary of the American Heart Association and American Thoracic Society Joint Guidelines for Pediatric Pulmonary Hypertension.Diagnostic Approach to Pulmonary Hypertension in Premature Neonates.Reported sildenafil side effects in pediatric pulmonary hypertension patients.Persistent Pulmonary Hypertension of the Newborn.Sildenafil add-on therapy in paediatric pulmonary arterial hypertension, experiences of a national referral centre.Temporal trends in use of sildenafil among pediatric patients.
P2860
Q26749283-2F2F8D96-96EF-442A-BDD6-CFE718F75BC3Q26996078-A5329D03-1D22-4EC7-A5B0-4FD82A2289A6Q28390572-E734CD89-84EA-4478-9D25-D21DCF5458E3Q33163446-D3D68876-703A-4A57-B9F3-E0FBBC7813D3Q33732209-979C5233-9CEE-45D9-8F7D-24FBC51C43FEQ33738631-9A5A2202-06BA-42F9-9B70-E7108C6E4B35Q33744291-AD9965CA-AC2F-434F-AEEA-7A9AAC728087Q33788441-A089F441-B7E0-4911-A0AD-FF3B91B0DCE4Q34479289-F2752387-5D55-4AA6-803E-11EE8A4078ECQ35156618-9597816C-FB8A-4F17-8868-4A2D4F5BA458Q35731631-587D2FD8-00D9-4B31-89B6-1E4133964EAEQ36730928-D0DFC9F2-D875-4EC5-ADA4-92BD2781A540Q36763080-801AA2CF-DF7E-4263-9763-2FE1E330B787Q37091197-F716C717-242E-4332-A0D5-2B7C969428DFQ37460315-66D36719-FBED-4581-BFCC-8A2ED12AB867Q37596144-8ED7DFC4-6DF0-4ED3-91F7-318D797C2877Q37630393-B1FBF4D3-46D2-49D6-A3E3-DCC51AC6190FQ37708606-1FBCE588-9429-45C1-9028-388AB156E468Q38118390-AB1D9F50-6094-4210-BA37-4757766FA393Q38119018-5973227B-A77D-4FAF-B47B-5A8814075A2FQ38128886-BE68C2CC-D422-410F-8B24-48FB6AE0B7B6Q38208579-C23F457D-4B37-49F8-96D9-81F41C956198Q38232339-2EA23A6C-DCF0-448A-BCA4-7CAADF7E76C5Q38249704-B333709C-6E01-41EA-B87B-6DD3F16D3D5DQ38341953-4CB3E05B-9A57-45F8-B51E-182150AA74F6Q38368957-60FF3E09-7DF2-4CF2-BC62-3811AD75EB7AQ38557105-5373D801-74B2-411E-BAE0-A341C318389DQ38642726-861B0259-948C-4931-8F9A-D4A6C3F87C8AQ38797632-B206CF14-A236-4EF4-81D6-B109521E9B98Q38943481-18A9F319-D651-4C79-BAD4-37B461EAED9BQ41127001-C2A9D044-7AEA-4852-9584-95906CE3EDEFQ41166895-04BD731E-5E70-41AD-8136-1CADC7E66B63Q41180077-95C03C89-8B11-41C1-BE08-0A00A02B2379Q41580751-281533EE-9CAC-4801-898A-5A00EA40AE31Q41631447-7753E14B-8197-4498-9665-04BC61DDEF89Q41671339-7F3998DC-6E00-4CEA-8D81-E2043249BE8EQ41900777-903AFE1F-9E81-4DF7-882F-0172A4721436Q42123924-924B135E-0274-4E3D-BEC8-A013EEF1EDB3Q43680261-05573F6A-3B90-476A-B4D0-E2F2694A4C8DQ44645278-4A62C0BA-C009-40E8-BC27-AEA7F7963C9A
P2860
Implications of the U.S. Food and Drug Administration warning against the use of sildenafil for the treatment of pediatric pulmonary hypertension.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Implications of the U.S. Food ...... iatric pulmonary hypertension.
@en
type
label
Implications of the U.S. Food ...... iatric pulmonary hypertension.
@en
prefLabel
Implications of the U.S. Food ...... iatric pulmonary hypertension.
@en
P2093
P2860
P50
P1476
Implications of the U.S. Food ...... diatric pulmonary hypertension
@en
P2093
David L Wessel
Ian Adatia
Jeffrey Fineman
John P Kinsella
Mary Mullen
Pediatric Pulmonary Hypertension Network (PPHNet)
Steven H Abman
Thomas Kulik
Tilman Humpl
Usha Krishnan
P2860
P304
P356
10.1164/RCCM.201210-1928PP
P407
P577
2012-12-06T00:00:00Z